Exosomes are tiny vesicles that ferry biomolecules like proteins and nucleic acids between cells. With properties inherited from their source cells, these versatile vesicles offer a safer, lower-cost, and higher-quality alternative to regenerative stem cell therapies. They can be enriched with compounds of interest, holding great promise as a new method for targeted drug delivery. Through strategic partnerships, ConvEyXO is leading the way in developing technologies to unlock the full therapeutic potential of exosomes at an affordable cost.


Exosomes play a key role in cell-to-cell communication and can modulate the behavior of nearby and distant cells.
Exosomes secreted from mesenchymal stem cells retain the immunomodulatory and anti-inflammatory properties of their source cells and present a promising alternative to cell therapies in regenerative medicine.
But potential applications of exosomes are many, as the vesicles can be loaded with molecules that amplify or change their activity, such as RNA, proteins, or any water-soluble drug compound.
Preclinical results confirm the potential of loaded exosomes in neurodegenerative, cardiovascular, musculoskeletal, auto immune, and infectious diseases, as well as oncology.

Both natural and loaded exosomes can be altered to precisely target specific cells or tissues by attaching ligands to their surface. The exosomes are then directed to the cells of interest to deliver the loaded compound. This reduces the dose of the compound and increases its potency on the targeted cells only.

The application of loading and/or targeting technology results in engineered exosomes.


At ConvEyXO, we are revolutionizing therapeutic interventions through our pioneering approach to extracellular vesicle (EV)-based treatments. Our focus on utilizing immortalized WJ MSC EVs, loaded with payloads tailored to specific needs, represents a paradigm shift in addressing a range of medical conditions. With a particular emphasis on fibrosis and chronic inflammation, we are committed to delivering targeted solutions that offer hope and healing to patients worldwide.

Our commitment to advancing medical science goes beyond mere intention; We’re actively broadening our therapeutic scope, delving into oncology, heart failure, NASH, and neurodegenerative diseases. In each field, we see a distinct opportunity to harness the potential of EV-based therapies, paving the way for novel treatments and renewed hope for patients worldwide.


With specialized manufacturing and loading deep technologies


There are several unique benefits offered by both the inherent properties of exosomes and those obtained by engineering:

    As they are incapable of proliferation in the body, the immunogenicity of exosomes is much lower than their source cells and they are non-tumorigenic.
    The targeted delivery of any loaded drug compounds reduces their side effects, which is extremely valuable in for example chemotherapies.
    Using immortalized stem cell lines to produce exosomes makes it possible to reach a much higher yield in a single batch than in the production of autologous or allogeneic stem cells, resulting in a lower cost per dose.
    Targeted delivery leads to a higher efficacy, meaning less exosomes need to be administered to the patient. This means more doses are obtained from a single batch, lowering the cost even further.
    Subcloned immortalized cell lines are much more consistent source material than mesenchymal stem cells isolated from a patient. This avoids batch-to-batch variation , leading to a consistent and high-quality product.


Together with our strategic partners, we are working to make therapeutic exosomes accessible in a cost-effective way. Their full potential will be unlocked by tackling the main technical challenges:

Would you like to learn more about our platform, or are you interested in collaborating? Get in touch!